Seminars in Nephrology
Volume 25, Issue 4 , Pages 210-214 , July 2005

Hypertension in Special Populations

  • Shawna D. Nesbitt

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Shawna D. Nesbitt, MD, MS, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8899.

References 

  1. Neel JV , Julius S , Weder A , et al.   Syndrome X (Is it Real?) . Gen Epidemiol . 1998;15:19–31
  2. Stamler J , Vacarro O , Neaton JD , et al.   Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial . Diabetes Care . 1993;16:434–444
  3. Sowers JR , Stump CS . Insights into the biology of diabetic vascular disease (What’s new?) . Am J Hypertens . 2004;17:2S–6S
  4. de Zeeuw D . Should albuminuria be a therapeutic target in patients with hypertension and diabetes . Am J Hypertens . 2004;17:11S–15S
  5. Julius S , Majahalme S , Palatini P . Antihypertensive treatment of patients with diabetes and hypertension . Am J Hypertens . 2001;14:310S–316S
  6. UK Prospective Diabetes Study (UKPDS) Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group . BMJ . 1998;338:645–652
  7. Hansson L , Zanchetti A , Carruthers SG , et al.  HOT Study Group   Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group . Lancet . 1998;351:1755–1762
  8. Curb JD , Pressel SL , Cutler JA , et al.  Systolic Hypertension in the Elderly Program Cooperative Research Group   Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension . JAMA . 1996;276:1886–1892
  9. Birkenhager WH , Staessen JH , Gasowski J , et al.   Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst-Eur) trial . J Nephrol . 2000;13:232–237
  10. Tuomilehto J , Rastenyte D , Birkenhager WH , et al.   Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension . N Engl J Med . 1999;340:677–684
  11. Hypertension Outcomes Prevention Evaluation (HOPE) Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (Results of the HOPE study and MICRO-HOPE substudy) . Lancet . 2000;355:253–259
  12. Lindholm LH , Ibsen H , Dahlof B , et al.   Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomized trial against atenolol) . Lancet . 2002;359:1004–1010
  13. Bakris GL , Williams M , Dworkin L , et al.  National Kidney Foundation and Diabetes Executive Committee Working Group   Preserving renal function in adults with hypertension and diabetes (A consensus approach) . Am J Kidney Dis . 2000;36:646–661
  14. Toto RD . Lessons learned from recent clinical trials in hypertensive diabetics (What’s good for the kidney is good for the heart and brain) . Am J Hypertens . 2004;17:7S–10S
  15. Parving H-H , Lehnert H , Brochner-Mortensen J , et al.   The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med . 2001;345:870–878
  16. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  17. Bloomgarden ZT . Angiotensin II receptor blockers and nephropathy trials . Diabetes Care . 2001;24:1834–1838
  18. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  19. Lewis EJ . The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes . Am J Hypertens . 2002;15:123S–128S
  20. Berl T , Hunsicker LG , Lewis JB , et al.   Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy . Ann Intern Med . 2003;138:542–549
  21. Barnett AH , Bain SC , Bouter P , et al.   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy . N Engl J Med . 2004;351:1952–1961
  22. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (The VALUE randomized trial) . Lancet . 2004;363:2022–2031
  23. Chobanian AV , Bakris GL , Black HR , et al.   Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension . 2003;42:1206–1252
  24. Vasan RS , Beiser A , Seshadri S , et al.   Residual lifetime risk for developing hypertension in middle-aged women and men (The Framingham Heart Study) . JAMA . 2002;287:1003–1010
  25. Hajjar I , Kotchen TA . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000 . JAMA . 2003;290:199–206
  26. Galarza CR , Alfie J , Waisman GD , et al.   Diastolic pressure underestimates age-related hemodynamic impairment . Hypertension . 1997;30:809–816
  27. Domanski M , Mitchell G , Pfeffer M , et al.   Pulse pressure and cardiovascular disease-related mortality . JAMA . 2002;287:2677–2683
  28. Chaudhry SI , Krumholz HM , Foody JM . Systolic hypertension in older persons . JAMA . 2004;292:1074–1080
  29. SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (final results of the Systolic Hypertension in the Elderly Program (SHEP)) . JAMA . 1991;265:3255–3264
  30. Staessen JA , Fagard R , Thijs L , et al.   Randomized, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators) . Lancet . 1997;350:757–764
  31. Liu L , Wang JG , Gong L , et al.   Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension . J Hypertens . 1998;16:1823–1829
  32. Rosenthal T , Oparil S . Hypertension in women . J Hum Hypertens . 2000;14:691–704
  33. Myers MG , Reeves RA . White coat effect in treated hypertensive patients (Sex differences) . J Hum Hypertens . 1995;9:729–733
  34. Hanes DS . Strategies for the treatment of hypertension in postmenopausal women . J Clin Hypertens . 1999;1:62–71
  35. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy . Am J Obstet Gynecol . 2000;183:S1–S22

PII: S0270-9295(05)00030-6

doi: 10.1016/j.semnephrol.2005.02.005

Seminars in Nephrology
Volume 25, Issue 4 , Pages 210-214 , July 2005

Article Tools